NASDAQ:ENVB

Enveric Biosciences Competitors

$2.38
+0.01 (+0.42 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.20
Now: $2.38
$2.39
50-Day Range
$2.37
MA: $3.22
$4.54
52-Week Range
$2.33
Now: $2.38
$21.20
Volume853,779 shs
Average Volume6.31 million shs
Market Capitalization$46.29 million
P/E RatioN/A
Dividend YieldN/A
Beta1.81

Competitors

Enveric Biosciences (NASDAQ:ENVB) Vs. PXLW, GSIT, SPI, MRAM, QUIK, and LPTH

Should you be buying ENVB stock or one of its competitors? Companies in the industry of "semiconductors & related devices" are considered alternatives and competitors to Enveric Biosciences, including Pixelworks (PXLW), GSI Technology (GSIT), SPI Energy (SPI), Everspin Technologies (MRAM), QuickLogic (QUIK), and LightPath Technologies (LPTH).

Pixelworks (NASDAQ:PXLW) and Enveric Biosciences (NASDAQ:ENVB) are both small-cap computer and technology companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, analyst recommendations, risk, institutional ownership, profitability and earnings.

Insider and Institutional Ownership

33.8% of Pixelworks shares are held by institutional investors. Comparatively, 0.8% of Enveric Biosciences shares are held by institutional investors. 4.6% of Pixelworks shares are held by company insiders. Comparatively, 4.4% of Enveric Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings for Pixelworks and Enveric Biosciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pixelworks01202.67
Enveric Biosciences0000N/A

Pixelworks currently has a consensus target price of $5.0833, indicating a potential upside of 59.85%. Given Pixelworks' higher possible upside, equities research analysts clearly believe Pixelworks is more favorable than Enveric Biosciences.

Profitability

This table compares Pixelworks and Enveric Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pixelworks-51.96%-31.06%-20.07%
Enveric Biosciences-19.34%-58.42%-25.44%

Volatility & Risk

Pixelworks has a beta of 2.21, indicating that its stock price is 121% more volatile than the S&P 500. Comparatively, Enveric Biosciences has a beta of 1.81, indicating that its stock price is 81% more volatile than the S&P 500.

Valuation and Earnings

This table compares Pixelworks and Enveric Biosciences' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pixelworks$68.75 million2.42$-9,080,000.00($0.12)-26.50
Enveric Biosciences$39.92 million1.16$-5,600,000.00N/AN/A

Enveric Biosciences has lower revenue, but higher earnings than Pixelworks.

Summary

Pixelworks beats Enveric Biosciences on 9 of the 11 factors compared between the two stocks.

GSI Technology (NASDAQ:GSIT) and Enveric Biosciences (NASDAQ:ENVB) are both small-cap computer and technology companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, profitability, institutional ownership and earnings.

Institutional and Insider Ownership

33.1% of GSI Technology shares are held by institutional investors. Comparatively, 0.8% of Enveric Biosciences shares are held by institutional investors. 35.3% of GSI Technology shares are held by company insiders. Comparatively, 4.4% of Enveric Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations and price targets for GSI Technology and Enveric Biosciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
GSI Technology01002.00
Enveric Biosciences0000N/A

Profitability

This table compares GSI Technology and Enveric Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
GSI Technology-61.99%-22.69%-19.86%
Enveric Biosciences-19.34%-58.42%-25.44%

Volatility & Risk

GSI Technology has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500. Comparatively, Enveric Biosciences has a beta of 1.81, indicating that its share price is 81% more volatile than the S&P 500.

Earnings & Valuation

This table compares GSI Technology and Enveric Biosciences' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GSI Technology$43.34 million3.62$-10,340,000.00N/AN/A
Enveric Biosciences$39.92 million1.16$-5,600,000.00N/AN/A

Enveric Biosciences has lower revenue, but higher earnings than GSI Technology.

Summary

GSI Technology beats Enveric Biosciences on 6 of the 9 factors compared between the two stocks.

SPI Energy (NASDAQ:SPI) and Enveric Biosciences (NASDAQ:ENVB) are both small-cap oils/energy companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, profitability, institutional ownership and earnings.

Institutional and Insider Ownership

6.3% of SPI Energy shares are held by institutional investors. Comparatively, 0.8% of Enveric Biosciences shares are held by institutional investors. 4.4% of Enveric Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations and price targets for SPI Energy and Enveric Biosciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
SPI Energy0000N/A
Enveric Biosciences0000N/A

Profitability

This table compares SPI Energy and Enveric Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SPI EnergyN/AN/AN/A
Enveric Biosciences-19.34%-58.42%-25.44%

Volatility & Risk

SPI Energy has a beta of 1.01, indicating that its share price is 1% more volatile than the S&P 500. Comparatively, Enveric Biosciences has a beta of 1.81, indicating that its share price is 81% more volatile than the S&P 500.

Earnings & Valuation

This table compares SPI Energy and Enveric Biosciences' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SPI Energy$97.88 million1.42$-15,260,000.00N/AN/A
Enveric Biosciences$39.92 million1.16$-5,600,000.00N/AN/A

Enveric Biosciences has lower revenue, but higher earnings than SPI Energy.

Summary

SPI Energy beats Enveric Biosciences on 6 of the 9 factors compared between the two stocks.

Everspin Technologies (NASDAQ:MRAM) and Enveric Biosciences (NASDAQ:ENVB) are both small-cap business services companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, profitability, institutional ownership and earnings.

Profitability

This table compares Everspin Technologies and Enveric Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Everspin Technologies-24.00%-44.04%-24.46%
Enveric Biosciences-19.34%-58.42%-25.44%

Analyst Ratings

This is a summary of recent recommendations and price targets for Everspin Technologies and Enveric Biosciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Everspin Technologies00103.00
Enveric Biosciences0000N/A

Everspin Technologies currently has a consensus price target of $10.00, indicating a potential upside of 91.94%. Given Everspin Technologies' higher possible upside, analysts clearly believe Everspin Technologies is more favorable than Enveric Biosciences.

Earnings & Valuation

This table compares Everspin Technologies and Enveric Biosciences' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Everspin Technologies$37.50 million2.67$-14,670,000.00($0.80)-6.51
Enveric Biosciences$39.92 million1.16$-5,600,000.00N/AN/A

Enveric Biosciences has higher revenue and earnings than Everspin Technologies.

Institutional and Insider Ownership

26.7% of Everspin Technologies shares are held by institutional investors. Comparatively, 0.8% of Enveric Biosciences shares are held by institutional investors. 23.6% of Everspin Technologies shares are held by company insiders. Comparatively, 4.4% of Enveric Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Volatility & Risk

Everspin Technologies has a beta of 1.65, indicating that its share price is 65% more volatile than the S&P 500. Comparatively, Enveric Biosciences has a beta of 1.81, indicating that its share price is 81% more volatile than the S&P 500.

Summary

Everspin Technologies beats Enveric Biosciences on 7 of the 11 factors compared between the two stocks.

Enveric Biosciences (NASDAQ:ENVB) and QuickLogic (NASDAQ:QUIK) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership and dividends.

Profitability

This table compares Enveric Biosciences and QuickLogic's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Enveric Biosciences-19.34%-58.42%-25.44%
QuickLogic-125.18%-78.90%-31.56%

Analyst Recommendations

This is a breakdown of current ratings and price targets for Enveric Biosciences and QuickLogic, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Enveric Biosciences0000N/A
QuickLogic01102.50

QuickLogic has a consensus price target of $8.00, indicating a potential upside of 21.77%. Given QuickLogic's higher possible upside, analysts plainly believe QuickLogic is more favorable than Enveric Biosciences.

Valuation and Earnings

This table compares Enveric Biosciences and QuickLogic's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Enveric Biosciences$39.92 million1.16$-5,600,000.00N/AN/A
QuickLogic$10.31 million7.18$-15,440,000.00($2.02)-3.25

Enveric Biosciences has higher revenue and earnings than QuickLogic.

Insider & Institutional Ownership

0.8% of Enveric Biosciences shares are held by institutional investors. Comparatively, 26.1% of QuickLogic shares are held by institutional investors. 4.4% of Enveric Biosciences shares are held by insiders. Comparatively, 2.9% of QuickLogic shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Risk & Volatility

Enveric Biosciences has a beta of 1.81, suggesting that its share price is 81% more volatile than the S&P 500. Comparatively, QuickLogic has a beta of 1.99, suggesting that its share price is 99% more volatile than the S&P 500.

Summary

Enveric Biosciences beats QuickLogic on 6 of the 11 factors compared between the two stocks.

Enveric Biosciences (NASDAQ:ENVB) and LightPath Technologies (NASDAQ:LPTH) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership and dividends.

Profitability

This table compares Enveric Biosciences and LightPath Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Enveric Biosciences-19.34%-58.42%-25.44%
LightPath Technologies6.33%7.46%5.42%

Analyst Recommendations

This is a breakdown of current ratings and price targets for Enveric Biosciences and LightPath Technologies, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Enveric Biosciences0000N/A
LightPath Technologies00303.00

LightPath Technologies has a consensus price target of $5.1667, indicating a potential upside of 90.65%. Given LightPath Technologies' higher possible upside, analysts plainly believe LightPath Technologies is more favorable than Enveric Biosciences.

Valuation and Earnings

This table compares Enveric Biosciences and LightPath Technologies' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Enveric Biosciences$39.92 million1.16$-5,600,000.00N/AN/A
LightPath Technologies$34.97 million2.03$870,000.00$0.0390.33

LightPath Technologies has lower revenue, but higher earnings than Enveric Biosciences.

Insider & Institutional Ownership

0.8% of Enveric Biosciences shares are held by institutional investors. Comparatively, 24.3% of LightPath Technologies shares are held by institutional investors. 4.4% of Enveric Biosciences shares are held by insiders. Comparatively, 11.5% of LightPath Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Risk & Volatility

Enveric Biosciences has a beta of 1.81, suggesting that its share price is 81% more volatile than the S&P 500. Comparatively, LightPath Technologies has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500.

Summary

LightPath Technologies beats Enveric Biosciences on 9 of the 11 factors compared between the two stocks.


Enveric Biosciences Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Pixelworks logo
PXLW
Pixelworks
1.2$3.18+2.5%$166.03 million$68.75 million-5.05Analyst Upgrade
News Coverage
GSI Technology logo
GSIT
GSI Technology
0.5$6.60+1.1%$157.07 million$43.34 million-7.86
SPI Energy logo
SPI
SPI Energy
0.5$6.22+2.7%$138.96 million$97.88 million0.00Increase in Short Interest
News Coverage
Gap Down
Everspin Technologies logo
MRAM
Everspin Technologies
1.2$5.21+0.2%$100.13 million$37.50 million-9.47
QuickLogic logo
QUIK
QuickLogic
1.4$6.57+2.6%$74.04 million$10.31 million-5.09Decrease in Short Interest
News Coverage
Gap Up
LightPath Technologies logo
LPTH
LightPath Technologies
1.7$2.71+5.2%$70.83 million$34.97 million33.88Decrease in Short Interest
News Coverage
Gap Down
Summit Wireless Technologies logo
WISA
Summit Wireless Technologies
1.1$2.77+0.0%$30.84 million$1.67 million-0.29News Coverage
Rubicon Technology logo
RBCN
Rubicon Technology
0.5$10.86+1.8%$26.30 million$3.53 million-45.25Gap Up
SuperCom logo
SPCB
SuperCom
0.6$1.36+1.5%$25.54 million$16.48 million0.00Gap Up
MoSys logo
MOSY
MoSys
0.5$3.66+1.6%$22.45 million$10.09 million-2.54Increase in Short Interest
News Coverage
SemiLEDs logo
LEDS
SemiLEDs
0.6$3.20+5.0%$12.99 million$6.07 million-12.80
This page was last updated on 4/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.